SUSAN FURTWENGLER: Open Payments
NPI 1518160688 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$403 in 17 payments from 11 companies in 2025. Trend: 2023 $916 · 2024 $906 · 2025 $403
Food & beverage: $403
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $138 |
| PFIZER INC. | 3 | $55 |
| ABBVIE INC. | 3 | $50 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
Products named: Ozempic, NURTEC ODT, REXULTI, QULIPTA, FARXIGA, Kerendia, GEMTESA, Wegovy.
Industry payments across AL — which companies pay providers there.
